How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology
Hypothesized renal hemodynamic effects of sodium-glucose... | Download Scientific Diagram
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol | Diabetes Technology & Therapeutics
SGLT2 Inhibitor-induced Euglycemic Diabetic Ketoacidosis - Renal Fellow Network
Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism - Ogawa - 2019 - Journal of Diabetes Investigation - Wiley Online Library
View of Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes | British Journal of Diabetes
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus - The Lancet Diabetes & Endocrinology
Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study) - Media Centre | EASD
Diabetes Distilled: Diabetic ketoacidosis with SGLT2 inhibitors - DiabetesontheNet
SGLT2 inhibitors – moving on with the evidence - DiabetesontheNet
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
Could SGLT2 Inhibitors Be Part of a New Treatment for Type 1 Diabetes? – BETTER
SGLT-2 Inhibitor Forxiga Approved for Adults with Type 1 Diabetes in Europe
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition - ScienceDirect
Addition of empagliflozin improves daytime glucose in type 1 diabetes
SGLT2 Inhibitors for Teens With Type 1 Diabetes
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/table1-minimizing-the-risk-of-diabetic.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
PDF) Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a treatment option for type-1 diabetes.
View of Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes | British Journal of Diabetes
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/figure1-potential-mechanisms-for-sodium-glucose.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature | Bentham Science
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
